Skip to main content
. Author manuscript; available in PMC: 2015 Feb 19.
Published in final edited form as: Nat Genet. 2014 Mar 23;46(5):427–429. doi: 10.1038/ng.2928

Figure 1.

Figure 1

Inactivating germline and somatic SMARCA4 mutations identified in SCCOHT. (a) Schematic of the SMARCA4 protein showing the location of the alterations identified in SCCOHT germline and tumor DNA samples. QLQ, Gln, Leu, Gln motif; HSA, helicase/SANT-associated domain; BRK, brahma and kismet domain; DEXDc, DEAD-like helicase superfamily domain; HELICc, helicase superfamily C-terminal domain; Bromo, bromodomain. (b) SMARCA4 immunohistochemistry analysis. Representative images of SMARCA4-negative SCCOHT tumors. Only two tumor cases showed positive nuclear staining for SMARCA4 (SCCO-018 shown). 200× magnification; scale bars, 100 μm. Immunohistochemistry of A549 cells for SMARCA4 and SMARCB1 was used for negative and antibody specificity controls, respectively. 400× magnification; scale bars, 50 μm. (c) SMARCA4 protein expression in representative cell lines from five major ovarian carcinoma subtypes (small cell, BIN-67; high-grade serous, OVSAYO; clear cell, TOV21G; endometrioid, A2780; low-grade serous, VOA1312), immortalized granulosa cells (SVOG) and an adult granulosa cell tumor cell line (KGN). Lung (A549) and gastric (GP202) carcinoma cell lines were included as negative and positive SMARCA4 expression controls, respectively.